Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | SVP & General Counsel | August 28, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QUEST DIAGNOSTICS INC
Report date August 28, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,557 |
Ending reported balance
After 2026-08-28 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 22,677 · Balance 60,234 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Row 2 · 2026-08-28 · Sale · Disposed 16,010 · Balance 44,224 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-08-28 · Sale · Disposed 6,237 · Balance 37,987 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-08-28 · Sale · Disposed 430 · Balance 37,557 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-08-28 · Gift · Disposed 1,000 · Balance 36,557 F5: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. |
| Non-Qualifed Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.17 · Expires 2030-02-18 | Direct | 0 |
Reported balance
After 2026-08-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-28 · Exercise / conversion · Disposed 22,677 · Balance 0 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F7: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Indirect401(k)/SDCP | 5,780 |
Reported balance
Holding disclosure · report date 2026-08-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,780 F6: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.
F6: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
F7: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 22,677 | $112.17 Strike: $112.17 | $2,543,679.09 |
DisclosureSEC source: 0001022079-26-000089 · wk-form4_1788208632.xml · derivative · entry 7 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,677 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F7 · derivative.exercise_date: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-26-000089 · wk-form4_1788208632.xml · nonDerivative · entry 5 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,557 F5 · kind: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 430 | $244.51 | $105,141.36 |
DisclosureSEC source: 0001022079-26-000089 · wk-form4_1788208632.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,557 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 6,237 | $243.63 | $1,519,504.72 |
DisclosureSEC source: 0001022079-26-000089 · wk-form4_1788208632.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,987 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 16,010 | $242.88 | $3,888,436.76 |
DisclosureSEC source: 0001022079-26-000089 · wk-form4_1788208632.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,224 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 22,677 | $112.17 | $2,543,679.09 |
DisclosureSEC source: 0001022079-26-000089 · wk-form4_1788208632.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 3,878 | $206.21 | $799,682.38 |
DisclosureSEC source: 0001022079-26-000029 · wk-form4_1772833467.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,557 F3 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,354 | $204.86 | $687,100.44 |
DisclosureSEC source: 0001022079-26-000029 · wk-form4_1772833467.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,435 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 7,232 | $204.86 | $1,481,547.52 |
DisclosureSEC source: 0001022079-26-000029 · wk-form4_1772833467.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,789 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 526 | $207.73 | $109,265.98 |
DisclosureSEC source: 0001022079-26-000022 · wk-form4_1772660322.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,557 F2 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 288 | $204.86 | $58,999.68 |
DisclosureSEC source: 0001022079-26-000022 · wk-form4_1772660322.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,083 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,111 | $204.83 | $227,566.13 |
DisclosureSEC source: 0001222679-26-000002 · wk-form4_1771625527.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,371 F3 · shares: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 9,289 | $0.00 Strike: $204.96 | $0.00 |
DisclosureSEC source: 0001222679-26-000002 · wk-form4_1771625527.xml · derivative · entry 6 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,289 Underlying: Common Stock · 9,289 shares Expires 2036-02-18 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 347 | $206.99 | $71,825.53 |
DisclosureSEC source: 0001222679-26-000002 · wk-form4_1771625527.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,482 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 301 | $210.01 | $63,213.01 |
DisclosureSEC source: 0001222679-26-000002 · wk-form4_1771625527.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,829 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001222679-26-000002 · wk-form4_1771625527.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,130 F1 · security: Represents an award of restricted stock units. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 227 | $103.57 Strike: $103.57 | $23,510.39 |
DisclosureSEC source: 0001022079-25-000203 · wk-form4_1759264615.xml · derivative · entry 5 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 227 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 144 | $188.66 | $27,166.77 |
DisclosureSEC source: 0001022079-25-000203 · wk-form4_1759264615.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,117 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $188.220 to $189.080. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 83 | $187.22 | $15,539.24 |
DisclosureSEC source: 0001022079-25-000203 · wk-form4_1759264615.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,261 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $187.00 to $187.480. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:36 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 227 | $103.57 | $23,510.39 |
DisclosureSEC source: 0001022079-25-000203 · wk-form4_1759264615.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 175 | $103.57 Strike: $103.57 | $18,124.75 |
DisclosureSEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · derivative · entry 7 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227 Underlying: Common Stock · 175 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 175 | $187.02 | $32,729.03 |
DisclosureSEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,117 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $187.000 to $187.350. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2025 Filed Sep 25, 2025 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 175 | $103.57 | $18,124.75 |
DisclosureSEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| September 23, 2025 Filed Sep 25, 2025 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 28,288 | $103.57 Strike: $103.57 | $2,929,788.16 |
DisclosureSEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · derivative · entry 6 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 402 Underlying: Common Stock · 28,288 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021. Read SEC document |
| September 23, 2025 Filed Sep 25, 2025 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 28,288 | $187.12 | $5,293,312.79 |
DisclosureSEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,117 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $187.000 to $187.880. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2025 Filed Sep 25, 2025 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 28,288 | $103.57 | $2,929,788.16 |
DisclosureSEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 01:00 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 4,643 | $170.00 | $789,310.00 |
DisclosureSEC source: 0001022079-25-000097 · wk-form4_1742432440.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,117 F1 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,906 | $173.74 | $678,628.44 |
DisclosureSEC source: 0001022079-25-000087 · wk-form4_1741210525.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,760 F4 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 8,549 | $173.74 | $1,485,303.26 |
DisclosureSEC source: 0001022079-25-000087 · wk-form4_1741210525.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,666 F3 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award dated approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 592 | $175.79 | $104,067.68 |
DisclosureSEC source: 0001022079-25-000087 · wk-form4_1741210525.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,117 F2 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 322 | $173.74 | $55,944.28 |
DisclosureSEC source: 0001022079-25-000087 · wk-form4_1741210525.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,709 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 528 | $172.61 | $91,138.08 |
DisclosureSEC source: 0001022079-25-000074 · wk-form4_1740778674.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,031 F2 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 286 | $171.75 | $49,120.50 |
DisclosureSEC source: 0001022079-25-000074 · wk-form4_1740778674.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,559 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 604 | $170.99 | $103,277.96 |
DisclosureSEC source: 0001022079-25-000058 · wk-form4_1740174264.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,845 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 374 | $169.71 | $63,471.54 |
DisclosureSEC source: 0001022079-25-000058 · wk-form4_1740174264.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,449 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 8,991 | $0.00 Strike: $165.30 | $0.00 |
DisclosureSEC source: 0001022079-25-000036 · wk-form4_1739572153.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,991 Underlying: Common Stock · 8,991 shares Expires 2035-02-12 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-25-000036 · wk-form4_1739572153.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,823 F1 · security: Represents an award of restricted stock units. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 35,146 | $86.63 Strike: $86.63 | $3,044,697.98 |
DisclosureSEC source: 0001022079-24-000208 · wk-form4_1733175791.xml · derivative · entry 5 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,146 shares Expires 2029-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 32,137 | $163.15 | $5,243,064.78 |
DisclosureSEC source: 0001022079-24-000208 · wk-form4_1733175791.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,478 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $162.705 to $163.615. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 3,009 | $162.26 | $488,236.73 |
DisclosureSEC source: 0001022079-24-000208 · wk-form4_1733175791.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,615 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $161.690 to $162.680. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 35,146 | $86.63 | $3,044,697.98 |
DisclosureSEC source: 0001022079-24-000208 · wk-form4_1733175791.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 32,551 | $95.80 Strike: $95.80 | $3,118,223.05 |
DisclosureSEC source: 0001022079-24-000176 · wk-form4_1725395450.xml · derivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,551 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 21, 2018, the second on February 21, 2019 and the final on February 21, 2020. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 32,551 | $154.97 | $5,044,516.36 |
DisclosureSEC source: 0001022079-24-000176 · wk-form4_1725395450.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,478 F1 · price: This transaction was executed in multiple trades at prices ranging from $154.890 to $155.455. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 32,551 | $95.80 | $3,118,223.05 |
DisclosureSEC source: 0001022079-24-000176 · wk-form4_1725395450.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 5,611 | $125.88 | $706,312.68 |
DisclosureSEC source: 0001022079-24-000083 · wk-form4_1709329804.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,478 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 456 | $126.36 | $57,620.16 |
DisclosureSEC source: 0001022079-24-000083 · wk-form4_1709329804.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,089 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 405 | $126.36 | $51,175.80 |
DisclosureSEC source: 0001022079-24-000083 · wk-form4_1709329804.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,545 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:34 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,825 | $125.02 | $353,181.50 |
DisclosureSEC source: 0001022079-24-000066 · wk-form4_1709069673.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,950 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:34 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 7,569 | $125.02 | $946,276.38 |
DisclosureSEC source: 0001022079-24-000066 · wk-form4_1709069673.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,775 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 661 | $126.14 | $83,378.54 |
DisclosureSEC source: 0001022079-24-000053 · wk-form4_1708724091.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,206 F2 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.